Corbus Pharmaceuticals reports Q2 EPS ($1.44), consensus ($1.33)

“The second half of 2025 is shaping up to be impactful, with scheduled data readouts anticipated for all three of our clinical programs,” said Yuval Cohen, Ph.D., Chief Executive Officer of Corbus. “We have been very pleased with the strong rate of enrollment in the CRB-701 study and look forward to presenting the Phase 1/2 dose expansion data at ESMO in October, which will include data from over 100 participants from the U.S. and Europe with HNSCC, cervical and mUC tumors. For our obesity drug CRB-913, we expect to present SAD/MAD data later this year and to initiate a Phase 1b dose-range finding study in the fourth quarter of 2025.”